NCT06543459View on ClinicalTrials.gov

To Evaluate the Effect of Single Oral Dose of MY008211A Tablets on QTc Interval in Healthy Subjects

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

August 10, 2024

Primary Completion Date

September 27, 2024

Study Completion Date

December 13, 2024

Conditions
Paroxysmal Nocturnal Hemoglobinuria
Interventions
DRUG

MY008211A tablets

Subjects of Group A receive MY008211A tablets on Day 1 of both Sequence, wash-out period is 6 Days at least.

DRUG

Placebo

Subjects of Group A receive placebo tablets on Day 1 of both Sequence, wash-out period is 6 Days at least.

Trial Locations (1)

100089

Peking University Third Hospital, Beijing

All Listed Sponsors
lead

Wuhan Createrna Science and Technology Co., Ltd

INDUSTRY

NCT06543459 - To Evaluate the Effect of Single Oral Dose of MY008211A Tablets on QTc Interval in Healthy Subjects | Biotech Hunter | Biotech Hunter